| MDMA | Q69488 |
| scholarly article | Q13442814 |
| P50 | author | Robert F Dannals | Q88679147 |
| P2093 | author name string | U Scheffel | |
| G A Ricaurte | |||
| Z Szabo | |||
| U D McCann | |||
| P2860 | cites work | An Algorithm for Least-Squares Estimation of Nonlinear Parameters | Q26778383 |
| Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging | Q34414286 | ||
| Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") | Q34720985 | ||
| Neurotoxicity of MDMA and related compounds: anatomic studies | Q37605816 | ||
| Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. | Q42489289 | ||
| Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). | Q44874777 | ||
| Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration | Q48088563 | ||
| Analysis of seasonal fluctuations of CSF monoamine metabolites and neuropeptides in normal controls: findings with 5HIAA and HVA. | Q48109727 | ||
| Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans | Q48153119 | ||
| Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo | Q48687914 | ||
| Fenfluramine-induced loss of serotonin transporters in baboon brain visualized with PET. | Q48832107 | ||
| Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter | Q48882689 | ||
| Correction for scattered radiation in a ring detector positron camera by integral transformation of the projections. | Q52708903 | ||
| Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations | Q67676454 | ||
| 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates | Q69050227 | ||
| Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 | Q71930952 | ||
| Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652 | Q72055422 | ||
| P433 | issue | 9138 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| P304 | page(s) | 1433-1437 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings | |
| P478 | volume | 352 |
| Q36062756 | "Ecstasy" toxicity to adolescent rats following an acute low binge dose |
| Q46800353 | "Ecstasy"-induced neurotoxicity: the contribution of functional brain imaging |
| Q36969134 | "The Great Unmentionable": Exploring the Pleasures and Benefits of Ecstasy from the Perspectives of Drug Users |
| Q40697558 | 3,4-Methylenedioxymethamphetamine ("Ecstasy") induces apoptosis of cultured rat liver cells. |
| Q42348445 | 3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus |
| Q35123814 | 3,4-methylenedioxyamphetamine upregulates p75 neurotrophin receptor protein expression in the rat brain |
| Q34437998 | 3,4-methylenedioxymethamphetamine (MDMA): a review |
| Q31431820 | 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation. |
| Q28546929 | 5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study |
| Q34190116 | A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA |
| Q36209977 | A brief overview of the clinical pharmacology of "club drugs". |
| Q36397237 | A clinical crossroads for MDMA. |
| Q43261577 | A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice |
| Q34476901 | A comprehensive review of MDMA and GHB: two common club drugs |
| Q34721218 | A contribution to the chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets |
| Q48381656 | A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users |
| Q40518413 | Acute and long-term effects of ecstasy |
| Q41040391 | Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study. |
| Q44610477 | Acute, sub‐acute and long‐term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users |
| Q31911068 | Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus |
| Q41859965 | Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms |
| Q34011998 | Agony and ecstasy: a review of MDMA effects and toxicity |
| Q34445553 | Alcohol, drugs and sexual function: a review |
| Q48301587 | Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. |
| Q44449172 | Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function |
| Q48188496 | Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery |
| Q35095703 | Altered states: the clinical effects of Ecstasy. |
| Q28567837 | An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA |
| Q35854864 | Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. |
| Q43821403 | Assessing long-term effects of MDMA (Ecstasy). |
| Q48187678 | Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study |
| Q46326792 | Brain serotonin transporter in human methamphetamine users |
| Q36829594 | Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users |
| Q44410467 | Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study |
| Q41669953 | Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake. |
| Q44847050 | Chronic MDMA (ecstasy) use, cognition and mood. |
| Q36020276 | Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy |
| Q32062587 | Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. |
| Q30351121 | Club drug use in Germany. |
| Q37789757 | Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation |
| Q46970793 | Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls |
| Q34310848 | Cognitive impairment in substance abuse |
| Q24677228 | Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions |
| Q44573235 | Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users |
| Q46504068 | Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe |
| Q41848022 | Could MDMA Promote Stemness Characteristics in Mouse Embryonic Stem Cells via mGlu5 Metabotropic Glutamate Receptors? |
| Q46533485 | Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study |
| Q58298077 | Deconstructing Ecstasy: The Politics Of Mdma Research |
| Q46763655 | Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days |
| Q34030711 | Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study |
| Q43179075 | Deficits of long-term memory in ecstasy users are related to cognitive complexity of the task |
| Q34232267 | Defining the states of consciousness |
| Q77818333 | Designer drugs in the general hospital |
| Q34272766 | Designer drugs: how dangerous are they? |
| Q45248986 | Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice |
| Q35017128 | Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys |
| Q46494945 | Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice |
| Q31680561 | Differential sensitivities to the lethal, but not the neurotoxic, effects of p-chloroamphetamine in inbred rat strains |
| Q30328470 | Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. |
| Q37439922 | EPIDEMIOLOGY MEETS CULTURAL STUDIES: STUDYING AND UNDERSTANDING YOUTH CULTURES, CLUBS AND DRUGS. |
| Q37082483 | Ecstasy (MDMA) and oral health |
| Q46046635 | Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective |
| Q43220452 | Ecstasy and the antecedents of illicit drug use. |
| Q28542888 | Ecstasy exposure & gender: examining components of verbal memory functioning |
| Q43841260 | Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug |
| Q35105548 | Ecstasy: America's New “Reefer Madness” |
| Q44418655 | Ecstasy: a review of scientific literature about MDMA |
| Q31033315 | Ecstasy: are animal data consistent between species and can they translate to humans? |
| Q40541816 | Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain |
| Q44730978 | Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. |
| Q73526592 | Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study |
| Q45224213 | Effect of ecstasy use on neuropsychological function: a study in Hong Kong |
| Q44111464 | Effects of (+/-) 3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans |
| Q44016730 | Effects of MDMA (ecstasy) use and abstention on serotonin neurons |
| Q48312053 | Effects of MDMA on blood glucose levels and brain glucose metabolism |
| Q36312733 | Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys |
| Q43821407 | Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons |
| Q34223687 | Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry |
| Q57062140 | Effects of the second-generation "bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice |
| Q46902890 | Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). |
| Q46808071 | Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naïve controls. |
| Q43698610 | Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans |
| Q48398184 | Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: results from a comparative study with d-amphetamine and methamphetamine |
| Q46691801 | Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy"). |
| Q45936086 | Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. |
| Q34634128 | Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users |
| Q28476219 | Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users |
| Q47322756 | Evolutionary and anthropological approaches towards understanding human need for psychotropic and mood altering substances |
| Q35757409 | Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons |
| Q43844504 | Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine ("Ecstasy") use history: psychobiological correlates |
| Q43743722 | Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms |
| Q43046156 | Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study |
| Q44954622 | Functional MRI study of working memory in MDMA users |
| Q35044762 | Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain |
| Q37402744 | Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. |
| Q40676299 | Glial cell line neurotrophic factor-family receptor alpha-1 is present in central neurons with distinct phenotypes |
| Q39725000 | High rates of club drug use and risky sexual practices among Hispanic men who have sex with men in Miami, Florida |
| Q48451818 | High-dose MDMA does not result in long-term changes in impulsivity in the rat. |
| Q34558846 | How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? |
| Q34820201 | Human Ecstasy use is associated with increased cortical excitability: an fMRI study. |
| Q36736116 | Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing |
| Q34359604 | Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research |
| Q34528465 | Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research |
| Q73755207 | Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs |
| Q28484412 | Illicit stimulant use in humans is associated with a long-term increase in tremor |
| Q28486143 | Illicit stimulant use is associated with abnormal substantia nigra morphology in humans |
| Q33637117 | Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV. |
| Q30495577 | Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) |
| Q44807875 | Impaired executive function in male MDMA ("ecstasy") users |
| Q48296924 | Improved statistical power of the multilinear reference tissue approach to the quantification of neuroreceptor ligand binding by regularization. |
| Q44557834 | In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. |
| Q44407124 | Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density |
| Q34637364 | Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing. |
| Q48622150 | Information processing speed in ecstasy (MDMA) users |
| Q46857178 | Initial deficit and recovery of function after MDMA preexposure in rats |
| Q46970767 | Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study |
| Q34218028 | Investigating the neurocognitive deficits associated with chronic drug misuse. |
| Q34982523 | Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach |
| Q34558819 | Involvement of serotonin in nicotine dependence: processes relevant to positive and negative regulation of drug intake |
| Q36831009 | Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms? |
| Q33864818 | Long term psychiatric and cognitive effects of MDMA use. |
| Q51082984 | Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. |
| Q46726341 | Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials. |
| Q45104174 | Loud noise enhances nigrostriatal dopamine toxicity induced by MDMA in mice |
| Q44212244 | Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy |
| Q34597927 | Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. |
| Q34626437 | MDMA ('ecstasy') and other 'club drugs'. The new epidemic |
| Q43925609 | MDMA ('ecstasy') use, and its association with high risk behaviors, mental health, and other factors among gay/bisexual men in New York City |
| Q35946697 | MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves |
| Q46970747 | MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the contemporary human and animal research perspective |
| Q73837153 | MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks |
| Q35415158 | MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study |
| Q90406870 | MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials |
| Q34280047 | MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain |
| Q43804924 | MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro |
| Q36643639 | MDMA use and neurocognition: a meta-analytic review |
| Q46004331 | Mediating MDMA-related harm: preloading and post-loading among Ecstasy-using youth. |
| Q48598882 | Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction |
| Q48598861 | Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users |
| Q44551784 | Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users |
| Q45062249 | Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users |
| Q36919640 | Meta-analysis of executive functioning in ecstasy/polydrug users |
| Q26768444 | Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users |
| Q36801473 | Methamphetamine causes microglial activation in the brains of human abusers. |
| Q73371204 | Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q44553347 | Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine |
| Q34976260 | Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. |
| Q30413718 | Monoamine transporter inhibitors and substrates as treatments for stimulant abuse |
| Q44359164 | Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users |
| Q48383462 | Motor cortex and corticospinal excitability in humans with a history of illicit stimulant use. |
| Q35671537 | N-acetylaspartate (NAA) correlates inversely with cannabis use in a frontal language processing region of neocortex in MDMA (Ecstasy) polydrug users: a 3 T magnetic resonance spectroscopy study |
| Q51976287 | N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. |
| Q35105569 | Negative experiences on Ecstasy: the role of drug, set and setting |
| Q44255973 | Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users. |
| Q24631230 | Neuroimaging and drug taking in primates |
| Q35692967 | Neuroimaging and mechanisms of drug abuse: interface of molecular imaging and molecular genetics |
| Q31033312 | Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects |
| Q30615539 | Neuroimaging in bipolar disorder: what have we learned? |
| Q37181415 | Neuroimaging in human MDMA (Ecstasy) users |
| Q36539089 | Neuroimaging research in human MDMA users: a review |
| Q34117191 | Neurological complications of drug abuse: pathophysiological mechanisms |
| Q37123827 | Neuropsychological function in ecstasy users: a study controlling for polydrug use. |
| Q36314030 | Neuroreceptor imaging in psychiatry: theory and applications. |
| Q35010538 | Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines |
| Q36797987 | Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms |
| Q73329501 | New drugs of abuse |
| Q51899385 | Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. |
| Q36255067 | Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users |
| Q44703093 | P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine |
| Q36209983 | Party drugs: properties, prevalence, patterns, and problems |
| Q51918971 | Patterns of memory dysfunction in current and 2-year abstinent MDMA users. |
| Q40448953 | Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. |
| Q26851461 | Pharmacological treatment of anxiety disorders: current treatments and future directions |
| Q52298136 | Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. |
| Q44462580 | Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations |
| Q44727574 | Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users |
| Q37461894 | Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance |
| Q48277665 | Positron emission tomography findings in heavy users of MDMA. |
| Q43766059 | Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report |
| Q44675333 | Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects |
| Q35105557 | Preventing Problems in Ecstasy Users: Reduce Use to Reduce Harm |
| Q39635436 | Priapism, ecstasy, and marijuana: is there a connection? |
| Q73290370 | Priapism: ecstasy related? |
| Q33586450 | Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study |
| Q48302266 | Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage |
| Q35589685 | Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval |
| Q40580538 | Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia |
| Q44894621 | Psychedelic drugs: the ups and downs of ecstasy |
| Q52009759 | Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. |
| Q24678394 | Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB |
| Q48181602 | Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine |
| Q34545356 | Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health |
| Q73901664 | Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration |
| Q46605178 | Reasoning deficits in ecstasy (MDMA) polydrug users |
| Q34558842 | Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity |
| Q48598854 | Recreational ecstasy use and depression |
| Q44057989 | Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. |
| Q36012329 | Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice |
| Q46477501 | Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol |
| Q33378451 | Reduced spontaneous eye blink rates in recreational cocaine users: evidence for dopaminergic hypoactivity |
| Q34565898 | Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? |
| Q44318123 | Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice |
| Q43587260 | Repeated exposure to MDMA triggers long-term plasticity of noradrenergic and serotonergic neurons |
| Q1964440 | Retracted article on dopaminergic neurotoxicity of MDMA |
| Q46679299 | Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. |
| Q80371421 | Science and the war on drugs: a hard habit to break |
| Q48874172 | Self-administered MDMA produces dose- and time-dependent serotonin deficits in the rat brain |
| Q44727559 | Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation |
| Q52170975 | Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. |
| Q44693605 | Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. |
| Q39950157 | Sexual dysfunction in men diagnosed as substance use disorder |
| Q45053309 | Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations |
| Q34618285 | Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users |
| Q47310452 | Social cognition and interaction in chronic users of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). |
| Q44019771 | Specific neurotoxicity of chronic use of ecstasy |
| Q42112531 | Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures |
| Q34386607 | Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan |
| Q24805157 | Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence |
| Q35892741 | Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907 |
| Q44589889 | Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter |
| Q78137048 | Ten years of 'ecstasy' |
| Q36274846 | The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine |
| Q40360036 | The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. |
| Q35105553 | The Politics of Ecstasy |
| Q36410792 | The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview |
| Q48149811 | The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain |
| Q43590243 | The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity |
| Q47966684 | The effect of acute tryptophan depletion on mood and impulsivity in polydrug ecstasy users |
| Q48319552 | The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users |
| Q46446358 | The effect of long-term repeated exposure to 3,4-methylenedioxymethamphetamine on cardiovascular and thermoregulatory changes. |
| Q34830911 | The effects and consequences of selected club drugs |
| Q37990456 | The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses |
| Q51980131 | The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic? |
| Q35092780 | The effects of ecstasy on liver function tests, blood glucose, and lipids profile of male rats |
| Q28069364 | The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies |
| Q51962585 | The ethics of conducting psychosis-inducing experiments. |
| Q34271828 | The impact of positive and negative ecstasy-related information on ecstasy use among college students: Results of a longitudinal study |
| Q38376332 | The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users |
| Q35568313 | The intoxicated child |
| Q37141888 | The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: rationale, evaluation and review of findings |
| Q21558652 | The neurotoxicity of amphetamines during the adolescent period |
| Q28361466 | The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs |
| Q43706709 | The structure of McN-5652. |
| Q37488576 | The two Na+ sites in the human serotonin transporter play distinct roles in the ion coupling and electrogenicity of transport |
| Q34025177 | The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine |
| Q77365969 | Toxic effect of MDMA on brain serotonin neurons |
| Q93921863 | Toxic effect of MDMA on brain serotonin neurons |
| Q48227576 | Toxic effect of MDMA on brain serotonin neurons |
| Q51985328 | Toxic effect of MDMA on brain serotonin neurons. |
| Q22252794 | Toxicity of amphetamines: an update |
| Q33864805 | Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). |
| Q38362000 | Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. |
| Q33957998 | Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study |
| Q44153719 | Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity |
| Q28486090 | Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users |
| Q44736256 | Visuospatial memory impairments in users of MDMA ('ecstasy'). |
| Q34201218 | [11C]-NS 4194 versus [11C]-DASB for PET imaging of serotonin transporters in living porcine brain |
| Q52298376 | [Anesthesia in drug addiction]. |
Search more.